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Abstract
Embryonic stem (ES) cell based therapy carries great potential in the treatment of
neurodegenerative diseases. However, before clinical application is realized, the safety, efficacy and
feasibility of this therapeutic approach must be established in animal models. The rhesus macaque
is physiologically and phylogenetically similar to the human, and therefore, is a clinically relevant
animal model for biomedical research, especially that focused on neurodegenerative conditions.
Undifferentiated monkey ES cells can be maintained in a pluripotent state for many passages, as
characterized by a collective repertoire of markers representing embryonic cell surface molecules,
enzymes and transcriptional factors. They can also be differentiated into lineage-specific
phenotypes of all three embryonic germ layers by epigenetic protocols. For cell-based therapy,
however, the quality of ES cells and their progeny must be ensured during the process of ES cell
propagation and differentiation. While only a limited number of primate ES cell lines have been
studied, it is likely that substantial inter-line variability exists. This implies that diverse ES cell lines
may differ in developmental stages, lineage commitment, karyotypic normalcy, gene expression, or
differentiation potential. These variables, inherited genetically and/or induced epigenetically, carry
obvious complications to therapeutic applications. Our laboratory has characterized and isolated
rhesus monkey ES cell lines from in vitro produced blastocysts. All tested cell lines carry the
potential to form pluripotent embryoid bodies and nestin-positive progenitor cells. These ES cell
progeny can be differentiated into phenotypes representing the endodermal, mesodermal and
ectodermal lineages. This review article describes the derivation of monkey ES cell lines,
characterization of the undifferentiated phenotype, and their differentiation into lineage-specific,
particularly neural, phenotypes. The promises and limitations of primate ES cell-based therapy are
also discussed.
Review
Embryonic stem (ES) cells were first derived from the
inner cell mass (ICM) of inbred mouse embryos in 1981
by Martin [1] and Evans and Kaufman [2]. Recently, ES
cells were successfully derived from non-human primate
and human embryos [3-5]. The National Institutes of
Health listed 64 human ES cell lines available for research
in 2001 [6]; however, only a few had been characterized
and studied. Similarly, less than 7 of the more than 20
monkey ES cell lines have been well characterized apart
from establishing pluripotency and genetic stability
[3,4,7-9]. Even in the mouse, most ES cell studies have
been performed with a single inbred mouse cell line
(strain 129). The extent of diversity among primate ES cell
lines is currently unknown.
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Primate and mouse ES cells are similar in their ability to
self-renew and differentiate into cells representing all
three embryonic germ layers [see [10-14] for review]. They
are different in cell/colony morphology, growth require-
ments and molecular signatures defining various develop-
mental stages. For example, leukemia inhibiting factor
(LIF), a component of the LIF-gp130-STAT3 signaling
pathway [12], is able to sustain undifferentiated murine,
but not primate, ES cell growth [13]. Thus, primate ES
cells are routinely cultured on a mouse feeder layer, i.e.,
mitotically suppressed mouse embryonic fibroblasts. The
use of feeder cells greatly limits the scaled up production
of undifferentiated primate ES cell populations and the
potential contamination by mouse cells is a safety concern
when considering transplantation.
Safety is one of the most important issues for ES cell-based
therapy. In addition to mouse cell contamination, tumor
formation or other somatic cell transformations from
grafted ES cell progeny must be considered. The likeli-
hood of transplanting pluripotent ES cells as a therapeutic
approach is low because of this problem. In contrast, their
differentiated progeny, which also survive and integrate
well in host tissues, are unlikely to form tumor cells.
Although differentiated ES cell progeny can be produced
in large quantity, enrichment and purification of the
desired phenotypes for transplantation must be ensured.
Clearly, the efficacy of ES cell-based transplantation must
be tested rigorously with each and every phenotype, pref-
erably in non-human primate models.
Derivation of monkey ES cell lines
Existing primate ES cell lines have not been directly com-
pared by different laboratory groups. A comparative
undertaking is important for several reasons. First, it helps
to standardize a protocol with simplified growth require-
ments for primate ES cell lines, or to derive a primate ES
cell line that replicates faster, is more amenable to sub-
cloning and can be maintained in the absence of feeder
layers or conditioned medium. Second, it characterizes
cell line-specific developmental potential for studies of
primate development or in drug discovery. Finally, it is
prudent for investigators to characterize several lines
before transplantation efforts begin. The quality of ES
cells among different cell lines, especially the ability to
self-renew and differentiate into a desired lineage, must be
ascertained, at least by in vitro assessment, before selection
for transplantation studies.
Rhesus monkey ES cell lines are available (con-
tact:wolfd@ohsu.edu) (Table 1) with eight "R" cell lines
(4 male and 4 female) derived from in vivo flushed blast-
ocysts [3] and seven cell lines derived from in vitro pro-
duced blastocysts (ORMES-1 to -7). The latter are under
development at Oregon National Primate Research
Center (ONPRC) [9]. Briefly, day 9 fully expanded blasto-
cysts were treated with a rabbit anti-rhesus spleen cell
antiserum (provided by Dr. James Thomson, Wisconsin
NPRC) for 3 h followed by exposure to a guinea pig com-
plement for 30 min [3,15]. This "immunosurgery" proce-
dure [15] effectively destroyed all trophoblastic cells,
exposing the ICM. After remnants of the trophoblastic
layer were cleared, individual ICM cells were plated onto
mouse feeder layers in ES cell medium. The expanded col-
onies were dissociated into small clumps of cells and
replated onto new feeder layers. After the first passaging,
colonies with ES cell-like morphology were selected for
propagation, characterization and storage. Most lines
(Table 1) are karyotypically normal with a diploid set of
42 chromosomes, however, ORMES-1 and -2 are stable,
balanced translocations (12,17 and 4,19, respectively;
denoted [t]). One ES cell line (366.4) has been stably
transfected with a reporter gene, eGFP, by Dr. James
Thomson. This eGFP-366.4 line has been enriched for
GFP positive cells by fluorescence-activated cell sorting
(FACS) in our laboratory. The pluripotent potential of
several lines has been tested in vivo following teratoma
formation in severely compromised immunodeficient
(SCID) mice or in vitro forming embryoid bodies (EB),
nestin-positive progenitor cells (NPC) and various glial
and neuronal phenotypes (see below).
Characterization of undifferentiated primate ES 
cells
Primate ES cells are routinely cultured on mouse feeder
cells because the molecular pathway and the key mole-
cules required to maintain pluripotency are unknown.
Our laboratory has adopted a manual method to select
undifferentiated monkey ES cells for propagation and dif-
ferentiation studies [16]. The procedure can enrich a mon-
key ES cell population to near homogeneity as indicated
by the high percentage of cells expressing several pluripo-
tent ES cell markers (Table 2). This unique repertoire of
markers includes the stage-specific embryonic antigens
(SSEA) 3 and 4, glycoproteins TRA-1-60 and TRA-1-81,
specific enzymes such as alkaline phosphatase and telom-
erase, and transcriptional factors Oct4, Rex1 and GDF-3
that are rapidly down regulated upon differentiation
[17,18]. The expression of markers such as SSEA-1 or Sox-
1 in primate ES cell populations indicates that some of
cells may have undergone differentiation. While none of
these markers alone carries absolute predictive value for
pluripotency, their presence as a group is highly informa-
tive (Table 2).
The ultimate identification of, and hence ability to com-
pare, pluripotent ES cell lines might be based on genome
wide expression analysis. By applying DNA microarray
technology, a set of "stemness" genes has been tentatively
identified in different murine stem cell populationsReproductive Biology and Endocrinology 2004, 2:41 http://www.rbej.com/content/2/1/41
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[19,20]. A similar approach has been initiated in parthe-
nogenetic monkey ES cells [21]. Extending the analysis to
genes that are up- or down-regulated upon differentiation
[22-24] allows identification of putative genes associated
with pluripotency that, in turn, could lead to the isolation
of factors critical to the propagation of undifferentiated ES
cells in a defined medium without the confounding con-
tamination of serum or feeder cells.
Differentiation of monkey ES cells
Primate ES cells spontaneously differentiate when cul-
tured in serum-containing medium but in the absence of
feeder cell support. This process is hastened by aggregat-
ing ES cells in hanging drops, in suspension or in over-
growth cultures [25]. In all cases, ES cells retain the ability
to differentiate into phenotypes representing the three
embryonic germ layers. In general, the hanging drop or
suspension approach is appropriate when chemicals are
used to induce lineage-specific differentiation. This is pri-
marily because both approaches result in the formation of
pluripotent embryoid bodies (EBs), spherical ES cell
aggregates. EBs form within days, allowing chemical
induction to occur early in differentiation without the
interference of serum or feeder cells. In contrast, the over-
growth approach usually takes weeks, enabling the selec-
tion of lineage-specific cells by morphological
assessment. For example, one interesting possibility based
on studies conducted in mice is the derivation of gametes
from ES cells. ES cell-derived gonadal germ cells were
obtained either by prolonged culture of overcrowded ES
cells forming primitive oocytes [26] or by EB formation
and induction forming spermatogonial cells [27,28].
Table 1: Availability and characterization of rhesus monkey ES cell lines
Cell Line Karyotype Passages Differentiation Potential
R366.4 42 XY, normal 6 to 60 Teratoma, EB, NPC, glial and neuronal phenotypes
R394.2 42 XX, normal 3 to 39 Teratoma, EB, NPC, glial and neuronal phenotypes
R475 42 XX, normal 5 to 16 Teratoma
R278.5 42 XY, normal 3 to 18 Teratoma
R420 42 XX, normal 3 to 16 Teratoma
R367B 42 XY, normal 2 to 8 Teratoma
R460 42 XY, normal 4 to 8 Teratoma
R456 42 XX, normal 3 to 7 Teratoma
ORMES-1 42 XY, 12/17 t 2 to 30 EB, NPC, glial and neuronal phenotypes
ORMES-2 42 XY, 4/19 t 2 to 16 EB, NPC, glial and neuronal phenotypes
ORMES-3 to be determined 2 to 10 to be determined
ORMES-4 to be determined 2 to 10 to be determined
ORMES-5 to be determined 2 to 10 to be determined
ORMES-6 42 XX, normal 2 to 10 to be determined
ORMES-7 to be determined 2 to 10 to be determined
GFP-366.4 42 XY, normal 47 to 57 EB, NPC, glial and neuronal phenotypes
Table 2: A conventional marker panel for identifying undifferentiated monkey ES cells
ES Cell Markers Description ES Cell Specificity
SSEA-3 embryonic stage-specific; glycolipid surface antigen Primate only
SSEA-4 embryonic stage-specific; glycolipid surface antigen Primate only
TRA-1-60 keratan sulphate-associated cell surface antigen Primate only
TRA-1-81 keratan sulphate-associated cell surface antigen Primate only
Oct4 POU-domain transcription factor Mouse and Primate
APtase alkaline phosphatase Mouse and Primate
Rex1 transcription factor Mouse and Primate
GDF-3 growth-differentiation factor 3 Mouse and Primate
Control markers
SSEA1 embryonic stage-specific; glycolipid surface antigen Mouse only
AFP alpha fetoprotein, endoderm Mouse and Primate
CTn-1 cardiac troponin-1, mesoderm Mouse and Primate
Sox1 transcription factor, ectoderm Mouse and Primate
HCG human chorionic gonadotropin; trophectoderm Primate onlyReproductive Biology and Endocrinology 2004, 2:41 http://www.rbej.com/content/2/1/41
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Note that it is unknown whether the gender orientation of
ES cell differentiation is genetically determined and/or
protocol-dependent. Certainly, epigenetic influences,
including cell-to-cell and cell-to-molecule interactions at
critical times, can bias ES cell differentiation toward a sin-
gle lineage. It has been postulated that ES cells in culture
will differentiate toward the neural lineage by default
[29], i.e., without genetic or epigenetic influences. In prac-
tice, spontaneous differentiation of ES cells rarely pro-
duces cells of a single lineage, although the proportion of
neural cells may be greater than other lineage-specific
cells.
In our laboratory, monkey ES cell-derived EBs have been
induced and differentiated into glial and neuronal pheno-
types (ectodermal lineage) [16] as well as insulin-produc-
ing, pancreatic beta cell-like phenotypes (endodermal
lineage) [see companion article by Dr. Linda Lester]. We
have also identified cardiomyocytes (mesodermal line-
age) after spontaneous differentiation of a monkey ES cell
line (ORMES-2) [unpublished observation]. Here, we
focus on the neural differentiation of monkey ES cells.
Neuronal differentiation by neural induction and selection
Following a neural selection protocol [30], monkey ES
cells aggregated in suspension culture formed EBs in
serum-containing medium within several days (Fig. 1A).
After EBs were cultured in the serum-free N1 medium for
7–10 days, they were maintained in a N2 medium supple-
mented with FGF2 for two weeks and plated onto polyor-
nithine/laminin surfaces [see ref. [16] for detailed
methods]. Immunostaining for neural progenitor markers
showed that >90% of cells in the population were nestin+
and Musashi1+ (Fig. 1B). These results indicate that the
neural selection protocol effectively eliminated cells of
non-neural lineages, allowing cells to differentiate into
neural progenitors that maintain their differentiated char-
acteristics for extensive periods. Neural progenitor cells
can be preserved by low temperature storage. For neuro-
nal phenotype differentiation, nestin+/Musashi1+ progen-
itor cells were dissociated into small clumps, plated onto
polyornithine/laminin-coated surfaces, and cultured in
N2 medium without FGF2 supplement (i.e., FGF2
removal and adherent culture) for 2–8 weeks. The differ-
entiated cells exhibited numerous neuronal processes, as
corroborated by the detection of the neuronal markers
TujIII, NeuN or MAP2 (Fig. 1C). They also expressed neu-
rotransmitter markers, i.e., tryptophan hydroxylase (TPH,
the rate-limiting enzyme for serotonin synthesis, Fig. 1D),
choline acetyltransferase (ChAT, the rate-limiting enzyme
for acetylcholine synthesis, Fig. 1E), and tyrosine hydrox-
ylase (TH, the rate-limiting enzyme for catecholamine
synthesis, Fig. 1F). The percentage of TPH+, ChAT+ and
TH+ phenotypes in the differentiated population was esti-
mated at >90%, >50% and <3%, respectively. Yield of the
TH+ phenotype was slightly increased by supplementing
L-Dopa in the N2 medium (Fig. 1G). After continued cul-
ture without FGF2 for 4–8 weeks, some neuronal cells
expressed markers of mature neurons such as alpha-nico-
tinic acetylcholine receptors (Fig. 1H) and estrogen recep-
tor-beta (Fig. 1I). Thus, FGF2 removal alone is very
effective in differentiating nestin+/Musashi1+ progenitor
cells into neuronal phenotypes, predominantly toward
the serotonergic lineage. Either this neural selection pro-
tocol limits TH+ phenotype differentiation or this process
requires epigenetic influences other than FGF2 removal
alone.
Based on the evidence that local environmental cues in
the adult brain can direct progenitor cells to differentiate
into host tissue-specific phenotypes [31-33], monkey ES
cells (from the ORMES-1 line) were subjected to neuronal
differentiation in the presence of crude extracts isolated
from adult monkey striatal tissues at the time of FGF2
removal. The striatum, a forebrain structure responsible
for movement coordination, contains dopaminergic neu-
ronal terminals whose cell bodies are located in the mid-
brain. Control cells were supplemented either with
cerebral cortical extracts or with nothing. The cells were
cultured under these conditions for 2–4 weeks. Medium
and extracts were refreshed daily. Cells in the cultures sup-
plemented with extracts appeared more widely spread and
greater in numbers within 2 weeks (data not shown). Cell
morphology was distinct among the 3 groups (Fig. 2A,2C
and 2E). Many cells expressed the neuronal filament Tuj
(Fig. 2B,2D and 2F). More TH+  neuronal cells were
observed in the culture supplemented with striatal tissue
extracts (Fig. 2F) compared to the culture with cortical
extracts (Fig. 2D). Only a few cells stained positive for TH
without extract supplement (Fig. 2B). These results sup-
port the concept that the striatum contains the chemical
cues required to direct the differentiation of monkey ES
cell-derived nestin+ progenitor cells into TH+ neuronal
cells.
A conceptually different method for TH+ neuronal differ-
entiation is to direct pluripotent ES cells into primitive
neuroectoderm-like precursor cells by stromal cell (i.e.,
PA6 cells) co-culture [34], HepG2 cell-conditioned
medium [35], or adherent culture [36]. Monkey neuroec-
toderm-like, precursor cell populations contain nearly
homogenous nestin+ and Musashi1+ progenitor cells that
can be differentiated into neuronal phenotypes [37].
Sequential additions of growth factors necessary for
embryonic midbrain development, i.e., sonic hedgehog
(SHH), FGF8, FGF2, brain-derived neurotrophic factor
(BDNF) and ascorbic acid, enrich mouse TH+ cell popula-
tions to >50%. These TH+  cells exhibit midbrain
dopaminergic neuronal properties [38]. Transplantation
of enriched dopaminergic neurons into the striatum of 6-Reproductive Biology and Endocrinology 2004, 2:41 http://www.rbej.com/content/2/1/41
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hydroxy-dopamine (6-OHDA)-lesioned mice or rats,
rodent models of Parkinson's disease exhibiting
dopamine-dependent deficiency in symmetrical move-
ment, alleviated apomorphine-induced movement asym-
metry [38-41].
Glial cell differentiation after adherent culture of nestin+/
Musashi1+ progenitor cells
The majority of monkey ES cells subjected to the neural
selection protocol differentiate into neuronal cells. How-
ever, approximately 10–15% of cells in the differentiated
Neuronal differentiation of monkey ES cells into embryoid bodies (EBs, panel A), progenitor cells expressing nestin and  musashi1 (panel B), neuronal cells expressing the neural filament TujIII (panel C) and neurotransmitter enzymes tryptophan  hydroxylase (TPH, panel D), choline acetyltransferase (ChAT, panel E) and tyrosine hydroxylase (TH, panel F and G) Figure 1
Neuronal differentiation of monkey ES cells into embryoid bodies (EBs, panel A), progenitor cells expressing nestin and 
musashi1 (panel B), neuronal cells expressing the neural filament TujIII (panel C) and neurotransmitter enzymes tryptophan 
hydroxylase (TPH, panel D), choline acetyltransferase (ChAT, panel E) and tyrosine hydroxylase (TH, panel F and G). Recep-
tors of mature neurons such as α4-nicotinic receptors (panel H) and estrogen receptor β (panel I) were also observed. The 
image in panel A was taken directly from an inverted microscope. Images in panels B-H were taken after fluorescence-based 
immunocytochemistry. The image in panel I was taken after staining with the classic, non-fluorescent procedure using bioti-
nylated antiserum and diaminobenzidine in the presence of nickel sulfate (shown in dark brown or black). Scale bars, when 
applied, are equivalent to 40 µm.
TujIII/DAPI C
TPH/DAPI D
ERE I
ChAT/DAPI E
H ChAT/D4-NAchR/NeuN NeuN/TH G
TH/MAP2 F
Nestin/Musashi1 B EBs AReproductive Biology and Endocrinology 2004, 2:41 http://www.rbej.com/content/2/1/41
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Neuronal differentiation of monkey ES cells under the influence of monkey brain tissue crude extracts Figure 2
Neuronal differentiation of monkey ES cells under the influence of monkey brain tissue crude extracts. Images were taken 
before (live) and after (fixed) immunostaining for TH (green) and TujIII (red). Co-expression of TH and TujIII appears in yellow. 
Cell nuclei were counterstained with DAPI (blue). A and B, without extracts; C and D, with cortical extracts; E and F, with stri-
atal extracts. Scale bars are equivalent to 50 µm.
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population express the glial cell marker, glial fibrillary
acidic protein (GFAP) [16], suggesting that a subpopula-
tion of phenotypes retains the characteristics of the glial
lineage. In a separate experiment, nestin+/Musashi1+ pro-
genitor cells were produced by neural selection of monkey
ES cells in overcrowding cultures. During the expansion
phase (prior to differentiation), nestin+/Musashi1+ pro-
genitor cells were plated onto adhesive culture dishes and
maintained in the N2 medium supplemented with FGF-2
for up to 6 months. Throughout this period, cells, appar-
ently originated from the nestin+/Musashi1+ progenitor
cells, attached to the surface of the culture dish and mul-
tiplied. The morphology and growth pattern of these cells
(Fig. 3A) bear resemblance to Schwann cell outgrowths
from cultured nerve explants isolated from perinatal mon-
keys [42]. When isolated and plated onto separate dishes,
these ES-derived cells formed monolayers, aggregated cell
bundles and floating spherical bodies, especially on
laminin-coated surfaces (Fig. 3B). Since Schwann cells are
characterized by genes such as p75, S-100, GFAP, O4,
GalC, SCIP, MBP, PLP and P0) [[43] for review; also see
Fig. 4], we examined the expression of these markers in
the differentiated cells and cell aggregates by immunocy-
tochemistry and RT-PCR. The differentiated population
contained phenotypes expressing nearly all tested markers
of Schwann cells (Fig. 3C,3D). Of particular interest is the
expression of myelin-associated proteins, MBP and PLP,
in these glial phenotypes (Fig. 3E,3F). The expression of
myelin proteins has also been reported in phenotypes
derived from neuronal differentiation of human ES cells
[44].
While the identity and function of monkey ES cell-derived
glial progeny remain to be elucidated, they represent a
mixture of phenotypes expressing markers typical of spe-
cific stages of Schwann cell development (Fig. 4). These
markers can be divided into 3 major groups. The first
group of genes and proteins, including p75, GFAP and
SCIP, has a temporal expression pattern, starting during
the development of immature Schwann cells and termi-
nating in mature, myelinating cells. The second group
contains S100, O4 and GC, which are expressed during
the progenitor or immature stage. The expression of these
genes and proteins continues in mature, myelinating
Schwann cells. The third group includes myelin-associ-
ated genes and proteins such as MBP and PLP that are
expressed only in the mature, myelinating Schwann cells.
As shown in Fig. 4, monkey ES cell-derived glial pheno-
types expressed protein markers indicative of all 3 major
Schwann cell developmental stages. The expression of sev-
eral gene markers has been confirmed by RT-PCR (Fig. 4,
insert), including p75, GFAP, MBP and PLP. The expres-
sion of endothelin receptor A (edtlRA) and integrin β1
(itgβ1), molecules that may play important roles in
Schwann cell maturation and adhesion [43], was also
observed. Quantification of marker expression in these
monkey ES cell-derived Schwann cell phenotypes, i.e.,
counting the number of cells expressing each marker, was
not performed. To delineate the temporal pattern of gene
and protein marker expression will require a chronologi-
cal study based on a quantitative assay. Nevertheless, the
results demonstrate that monkey ES cells can be differen-
tiated into a mixture of phenotypes that can be classified
as cells in the Schwann cell lineage, including those
expressing myelinating proteins. Such phenotypes have
the potential to be enriched, defined, and developed into
a suitable cell source for studying the safety, efficacy and
feasibility of replacement therapy with myelinating cells
in animal models of demyelinating disorders, such as
multiple sclerosis and spinal cord injuries [45-52].
Perspectives and limitations of ES cell research 
and applications
Since the isolation of human ES cells [5], we have wit-
nessed an explosion in ES cell research based on the
expectation that these cells will become a valuable source
for replacement therapy to cure cellular degenerative dis-
eases. At the same time, adult stem cells isolated from var-
ious tissues carry similar expectations for regenerative
medicine, given that de-differentiation (from tissue-spe-
cific stem cells to pluripotent stem cells) and trans-differ-
entiation (between tissue-specific stem cells) become
possible [53-55].
ES cell-based therapy is a viable approach to cure degener-
ative conditions such as Alzheimer's disease, Parkinson's
disease, multiple sclerosis, spinal cord injury, diabetes
and cardiac dystrophy, to name a few. The road to achieve
these goals will be long, and the challenge ahead is daunt-
ing. Some of the more immediate limitations in primate
ES cell research and applications include the following:
(1) The optimization of undifferentiated ES cell culture is
key to standardize successful culture of undifferentiated
primate ES cells and to scale-up the production of differ-
entiated progeny for transplantation. The solution may
rely on the discovery of "stemness" genes and their signal-
ing pathways. This requirement cannot be circumvented
by using mouse feeder cell-conditioned medium [56] or
human cell co-cultures [57], but these alternatives are
helpful in animal research. A feeder layer- and serum-free
culture system for human ES cells employing a combina-
tion of serum replacement and growth factors [58] has
been reported. Validation of this method in different pri-
mate ES cell lines will be valuable. Methods to quantita-
tively identify and isolate undifferentiated ES cells from
spontaneously differentiated phenotypes during culture
must be established. Moreover, the quality of pluripotent
ES cells over multiple passages, such as chromosomal nor-
malcy and differentiation potential, must be maintained.Reproductive Biology and Endocrinology 2004, 2:41 http://www.rbej.com/content/2/1/41
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Differentiation of monkey ES cells into glial phenotypes Figure 3
Differentiation of monkey ES cells into glial phenotypes. Panel A, morphology in culture; Panel B, aggregated glial cell bundles 
and spheres cultured on laminin-coated glass coverslips; Panel C, expression of Schwann cell markers S100 and GFAP; Panel D, 
expression of Schwann cell markers GFAP and p75 (NGFR); Panel E, expression of myelin protein MBP and Schwann cell 
marker GC; Panel F, expression of myelin protein PLP and neuronal marker MAP2C. Panel G shows the temporal pattern of 
Schwann cell molecular signatures during development and a mixture of glial phenotypes derived from monkey ES cells 
expressing these Schwann cell markers as determined by immuocytochemistry (panel H) and RT-PCR (panel I).
PLP /MAP2C F MBP/GC/DAPI E
S100/GFAP/DAPI C
B AReproductive Biology and Endocrinology 2004, 2:41 http://www.rbej.com/content/2/1/41
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(2) A characterization and comparison among primate ES
cell lines is essential to define line specificity. The full
potential of ES cell applications can not be realized by a
few cell lines studied by a small number of laboratories. A
concerted effort to create an ES cell bank with well-charac-
terized cell lines and standardized culture procedures for
distribution to scientists will greatly facilitate primate ES
cell research. Creating new monkey ES cell lines for unbi-
ased characterization should provide invaluable informa-
tion about ES cell line diversity that is unable to be
performed at the present time in the United States with
federal funding on human ES cell lines.
(3) Phenotype-specific differentiation and enrichment
protocols are critical to the application of ES cells for ther-
apy. Differentiation protocols derived from mouse ES cell
research must be applied to primate ES cells as soon as fea-
sible, as it is most certain that modifications will have to
be made to overcome species differences. Enrichment of
the desired phenotype for transplantation will probably
A schematic presentation of Schwann cell markers expressed during various developmental stages Figure 4
A schematic presentation of Schwann cell markers expressed during various developmental stages. These markers are tenta-
tively divided into 3 groups. Group 1 are genes and proteins, including p75, GFAP and SCIP (shown in blue), that express tem-
porally during the development between immature Schwann cells and matured, myelinating cells. Group 2 markers include 
S100, O4 and GC (shown in red) that express during the progenitor or immature stages and continue into matured, myelinat-
ing Schwann cells. Group 3 markers include myelinating genes and proteins such as MBP and PLP (shown in green) that express 
only in the mature stage of myelinating Schwann cells. Monkey ES cell-derived glial phenotypes formed cell bundles and aggre-
gates that expressed markers of all 3 groups (shown in immunofluorescence green images; nuclei were counter-stained with 
DAPI in blue color), except GC, which expressed in some, but not all, samples (image not shown). The insert shows gene 
markers detected by RT-PCR in these monkey ES cell-derived glial phenotypes.
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be essential, with the quality of primate ES cells or prog-
eny ensured after enrichment.
(4) Genetic manipulations such as functional gene knock-
ins, including disease-specific genes, differentiation-pro-
moting genes and immunocompatible genes are highly
desirable. Recent success in gene transfer by homologous
recombination [59] and lentiviral vectors [60] is encour-
aging, but these procedures need to be applied to other
cell lines, by other laboratories, and improved for better
efficiency. The quality and potential of genetically modi-
fied primate ES cells should be tested rigorously in animal
models.
(5) Development of animal models for transplantation
studies is a crucial step toward successful clinical applica-
tions. In many cases, results using rodent models cannot
be translated to human patients. Currently there are no
discriminative non-human primate models of cellular
degenerative diseases because gene-knockout and cloning
procedures in the monkey are both time consuming and
technically challenging. A few experimental models, such
as MPTP-induced hemiparkinsonian monkeys [61], are
therefore extremely valuable for ES cell-based therapeutic
studies. The development of additional disease models
with nonhuman primates is urgent.
Conclusions
At least 15 rhesus monkey ES cells lines are available at the
Oregon National Primate Research Center. These cell lines
have been characterized by their chromosomal normalcy,
growth patterns and differentiation potential. The
pluripotency of undifferentiated monkey ES cells is
defined by a panel of molecular signatures that include
embryonic surface antigens, enzymes and transcriptional
factors. Highly purified nestin+/Musashi1+  progenitor
cells can be produced by a neural selection protocol.
These progenitor cells are multipotent, if not pluripotent,
capable of differentiating into insulin-producing
endodermal cells, various neuronal phenotypes and glial
cells expressing Schwann cell markers and myelinating
proteins. Differentiation into certain populations, such as
the serotonergic phenotypes, is induced by the selection
protocol. Differentiation into other lineages, such as the
dopaminergic phenotypes, is either inhibited or requires
additional epigenetic influences such as those present in
extracts of the dopaminergic striatum. However, enrich-
ment of dopaminergic phenotypes by directional differen-
tiation of mouse ES cells followed by appropriate growth
factor induction has been successful. The potential exists
for the differentiation and enrichment of monkey ES cells
into dopaminergic neurons or myelinating glial pheno-
types that serve as suitable cell sources for transplantation
studies in animal models of Parkinson Disease, multiple
sclerosis and spinal cord injury. Such translational stud-
ies, particularly in nonhuman primate models, are critical
steps to understand the safety, feasibility and efficacy of ES
cell-based therapy for the treatment of neural degenera-
tive diseases.
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